SI0812588T1 - Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder - Google Patents

Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder

Info

Publication number
SI0812588T1
SI0812588T1 SI9630694T SI9630694T SI0812588T1 SI 0812588 T1 SI0812588 T1 SI 0812588T1 SI 9630694 T SI9630694 T SI 9630694T SI 9630694 T SI9630694 T SI 9630694T SI 0812588 T1 SI0812588 T1 SI 0812588T1
Authority
SI
Slovenia
Prior art keywords
octylphenyl
diol
propane
ethyl
amino
Prior art date
Application number
SI9630694T
Other languages
English (en)
Slovenian (sl)
Inventor
Tsuneo Yoshitomi Pharmaceutical Ind. Ltd. FUJII
Tadashi Yoshitomi Pharmaceutical Ind Ltd MISHINA
Koji Yoshitomi Pharmaceutical Ind. Ltd. TESHIMA
Tomonori Yoshitomi Pharm. Ind. Ltd. IMAYOSHI
Original Assignee
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation filed Critical Mitsubishi Pharma Corporation
Publication of SI0812588T1 publication Critical patent/SI0812588T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SI9630694T 1995-12-28 1996-12-24 Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder SI0812588T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34250395 1995-12-28
PCT/JP1996/003757 WO1997024112A1 (fr) 1995-12-28 1996-12-24 Preparation a usage externe

Publications (1)

Publication Number Publication Date
SI0812588T1 true SI0812588T1 (en) 2005-02-28

Family

ID=18354257

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630694T SI0812588T1 (en) 1995-12-28 1996-12-24 Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder

Country Status (16)

Country Link
US (2) US6121329A (cs)
EP (1) EP0812588B1 (cs)
AT (1) ATE279185T1 (cs)
AU (1) AU705320B2 (cs)
CA (1) CA2213989C (cs)
CZ (1) CZ285953B6 (cs)
DE (1) DE69633613T2 (cs)
ES (1) ES2230571T3 (cs)
HU (1) HU224814B1 (cs)
IL (1) IL121625A (cs)
NZ (1) NZ324453A (cs)
PT (1) PT812588E (cs)
RU (1) RU2156127C2 (cs)
SI (1) SI0812588T1 (cs)
SK (1) SK282225B6 (cs)
WO (1) WO1997024112A1 (cs)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JP4153563B2 (ja) 1997-02-27 2008-09-24 ノバルティス アーゲー 医薬組成物
CN1161117C (zh) 1998-04-27 2004-08-11 藤泽药品工业株式会社 药物组合物
US20020006901A1 (en) * 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US7683044B2 (en) * 1999-03-25 2010-03-23 Center For Molecular Medicine And Immunology Sphingomyelin therapy of autoimmune disease
CA2707691C (en) * 1999-03-25 2013-09-03 Center For Molecular Medicine And Immunology Sphingomyelin containing preparation
JP2004507552A (ja) 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
PT1368015E (pt) * 2001-02-22 2006-12-29 Novartis Ag Utilização de agentes de alojamento linfocitário acelerado no fabrico de um medicamento para o tratamento da função de enxerto retardada
US20030124174A1 (en) * 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
AU2003233119A1 (en) 2002-05-08 2003-11-11 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
RU2220738C1 (ru) * 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Средство для лечения ринита
KR20050092429A (ko) * 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
DE602004017847D1 (de) 2003-04-08 2009-01-02 Novartis Ag Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
RU2233163C1 (ru) * 2003-04-30 2004-07-27 Государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт" Способ лечения акантолитической пузырчатки
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
CA2538103A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Synergistic antimicrobial compositions comprising an antimicrobial lipid component and an enhancer component
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
GB0324210D0 (en) 2003-10-15 2003-11-19 Novartis Ag Organic compounds
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CA2557536C (en) 2004-02-24 2010-07-13 Sankyo Company Limited Amino alcohol compound
US20050232894A1 (en) * 2004-04-20 2005-10-20 Weiner Gregory M Antimicrobial skin treatment composition and methods for producing and using an antimicrobial skin treatment composition
CN1993115B (zh) * 2004-07-30 2011-12-28 诺瓦提斯公司 2-氨基-1,3-丙二醇化合物的制剂
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US20060210604A1 (en) * 2004-10-04 2006-09-21 Eric Dadey Ocular delivery of polymeric delivery formulations
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
ATE511838T1 (de) 2005-03-10 2011-06-15 3M Innovative Properties Co Antimikrobielle zusammensetzungen mit hydroxycarboxylsäureestern
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
US8476319B2 (en) 2005-03-10 2013-07-02 3M Innovative Properties Company Methods of treating ear infections
EP2497460A1 (en) 2005-03-10 2012-09-12 3M Innovative Properties Co. Methods of reducing microbial contamination
WO2006102611A2 (en) * 2005-03-24 2006-09-28 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia
ES2393675T3 (es) * 2005-07-13 2012-12-27 Santen Pharmaceutical Co., Ltd. Composición conservante para uso oftálmico
AU2007217810B2 (en) * 2006-02-21 2012-10-11 The Ohio State University Research Foundation Anticancer agents
EP2046315B1 (en) * 2006-06-02 2013-04-10 The Ohio State University Research Foundation Therapeutic agents for the treatment of mantle cell lymphoma
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
EP2209493A2 (en) 2007-10-12 2010-07-28 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
RU2361604C1 (ru) * 2007-10-29 2009-07-20 Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) Способ лечения атопического дерматита
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
US8461362B2 (en) * 2009-04-13 2013-06-11 The Ohio State University Research Foundation Protein phosphatase 2A-activating agents
AU2010236323A1 (en) * 2009-04-17 2011-11-24 The Ohio State University Research Foundation Antiadhesion agents
KR20120032538A (ko) * 2009-07-24 2012-04-05 라티오팜 게엠베하 핀골리모드 염의 제조 방법
CN101966145A (zh) * 2010-09-21 2011-02-09 浙江大学 2-氨基-2-(2-[4-辛基苯基]乙基)-1,3-丙二醇盐酸盐制剂及其制备方法
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
CN105611917A (zh) 2013-10-11 2016-05-25 帝国制药美国公司 局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
CA3049402A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
US10798783B2 (en) * 2017-02-15 2020-10-06 Continuous Composites Inc. Additively manufactured composite heater
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
CN115300508A (zh) * 2017-07-05 2022-11-08 艾缇亚(上海)制药有限公司 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU374086A1 (ru) * 1971-06-11 1973-03-20 ЛЕКАРСТВЕННОЕ СРЕДСТВО''^ --''ОсНАЯ'•'^^^bju;r---jc^'-;^..':. :0 •--.:А |:'*''~'"~~ •' - ——«-.«aSJ^iH.
SE7510988L (sv) * 1975-10-01 1977-04-02 Draco Ab Nya farmaceutiskt aktiva foreningar
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
EP0501579A1 (en) * 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Naphthalene lactones as inhibitors of leukotriene biosynthesis
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
IT1252866B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli con acidi policarbossilici atti alla modulazione dei mastociti nei processi infiammatori su base neuroimmunogenica
IT1252865B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
DK0627406T3 (da) * 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
JPH06256182A (ja) * 1993-03-05 1994-09-13 L T T Kenkyusho:Kk 外用製剤
JPH07188046A (ja) * 1993-12-27 1995-07-25 L T T Kenkyusho:Kk シクロスポリン含有外用治療薬及びその製造方法
WO1995022343A1 (fr) * 1994-02-17 1995-08-24 Shiseido Company, Ltd. Composition d'emulsion a base de cyclosporine
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法

Also Published As

Publication number Publication date
CA2213989C (en) 2007-05-29
NZ324453A (en) 2000-03-27
DE69633613D1 (de) 2004-11-18
US6121329A (en) 2000-09-19
IL121625A0 (en) 1998-02-08
HUP9800034A2 (hu) 1999-05-28
US6197829B1 (en) 2001-03-06
AU1172997A (en) 1997-07-28
CA2213989A1 (en) 1997-07-10
ATE279185T1 (de) 2004-10-15
IL121625A (en) 2001-09-13
CZ285953B6 (cs) 1999-12-15
EP0812588A1 (en) 1997-12-17
EP0812588A4 (en) 2002-11-06
SK282225B6 (sk) 2001-12-03
RU2156127C2 (ru) 2000-09-20
CZ270497A3 (cs) 1998-01-14
EP0812588B1 (en) 2004-10-13
WO1997024112A1 (fr) 1997-07-10
AU705320B2 (en) 1999-05-20
HU224814B1 (en) 2006-02-28
ES2230571T3 (es) 2005-05-01
HUP9800034A3 (en) 1999-12-28
PT812588E (pt) 2005-01-31
DE69633613T2 (de) 2006-02-09
SK115797A3 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
SI0812588T1 (en) Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
FI935847A0 (fi) L-DOPA-esterkompositioner
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
NL970006I2 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
BG101118A (en) Therapeutical compounds
FI914919A7 (fi) AIDS-potilaiden neurologisten sairauksien hoidossa tehokkaat farmaseuttiset koostumukset, jotka sisältävät vaikuttavana aineena vähintään yhtä yhdistettä, joka on valittu ryhmästä, joka käsittää S-adenosyyli -L-metioniinisuolan, 5-metyylitetrahydrofool
EP0990440A4 (en) Drug composition
TW362973B (en) Use of 2-anino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a composition having an antidepressant activity
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
EP0744176A3 (en) Methods for inhibiting bone loss
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
US6066676A (en) Pharmaceutical composition and methods for using it
HUP9900945A2 (hu) Nukleozidanalógok herpes simplex vírus fertőzések kombinációs terápiájában
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
DK248987A (da) Farmaceutiske praeparater til forbedring af sammensaetningen af lipider i blod
WO1999006438A3 (en) Compounds with anti-ks and anti-hiv activity
WO2000041526A3 (en) Use of s-triazines for treating apicomplexan parasitic infections
ITRM910003A0 (it) Estratto idroalcolico di erbe e piante medicinali per la cura di: tendiniti-nevriti- siatalgie-dolori reumatici, articolari, cervicali torcicolli.
FR2759586B1 (fr) Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol
WO1994016705A3 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
UA30143A (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
RU95116290A (ru) Применение 5-морфолино-3-(4-хлорбензилиденамин)-2-оксазолидинона, фармацевтическая композиция на его основе, способ лечения
RU99114313A (ru) Шарики "биосан" для лечения кольпитов различного генеза и способ лечения кольпитов различного генеза
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof